Clinical implications of HER-2 and p53 in tazane-based and anthracycline-based neoadjuvant chemotherapy in breast cancer
Objective: To evaluate the predictive value of human epidermal growth factor receptor(HER)-2 and p53 in anthracycline-based and taxane-based neoadjuvant chemotherapy (NAC) in breast cancer.Patients and Methods: Sixty-two women with locally advanced breast carcinoma were enrolled in the study between Jan 2006 and Jun 2008 and histologically diagnosed as breast carcinoma by core needle biopsy of the breast. Forty were treated with anthracycline-based NAC(the anthracycline group), including CE regimen and CEF regimen with the dosage of epirubicin 60mg/m2, 70mg/m2 or 80mg/m2, and the dosage was dependent on the patients physical status; twenty-two patients were treated with taxane-based NAC(the taxane group), including TP regimen(docetaxel and cisplatin), TX regimen(docetaxel and capecitabine), TE regimen(docetaxel and epirubicin) and T regimen(single-agent taxane), and the dosage of paclitaxel is 175mg/m2 or the dosage of docetaxel is 75mg/m2; Chemotherapy was prescribed for the patients every 3 weeks. In fact, thirty-six cases received 2 cycles, seven cases received 3cycles and nineteen cases received 4 or more cycles.
breast cancer neoadjuvant chemotherapy HER-2 P53 tazane anthracycline
Xiao-lan Wang Fan Yao Yun-fei Wu Xin-yu Zheng Ji-guang Li Feng Jin
Department of breast surgery, the first hospital of China Medical University.Shenyang 110001, China
国际会议
上海
英文
94-95
2008-10-01（万方平台首次上网日期，不代表论文的发表时间）